Factbox: Bayer's new CEO: long-time Roche, Genentech executive, Bill Anderson

Roche Pharmaceuticals CEO William “Bill” Anderson speaks during an interview on the sidelines of the 38th Annual JP Morgan Healthcare Conference in San Francisco
William “Bill” Anderson, chief executive officer of Roche Pharmaceuticals, speaks during an interview on the sidelines of the 38th Annual JP Morgan Healthcare Conference in San Francisco, California, U.S. January 13, 2020. REUTERS/Stephen Lam/File Photo

LONDON, Feb 8 (Reuters) - Bayer (BAYGn.DE) bowed to investor pressure on Wednesday and named Bill Anderson, most recently head of Roche's (ROG.S) pharmaceuticals business, to take over from Werner Baumann as its CEO in June.

Here are some key facts about the career about the 56-year-old American who will run the nearly 160-year-old German drugmaker:

He is a chemical engineer by education and has worked for Genentech and its parent Roche since 2006

CAREER:

1989: started his career at Ethyl Corp, a U.S.-based fuel additives company, with postings in Belgium and the Netherlands

1995: joined Raychem Corp., a U.S. technology and electronics firm

1997-2006: worked at Biogen (BIIB.O) in the United States, UK and Ireland; roles included running its neurology unit, its largest business

2006: joined Genentech as senior vice president, immunology and ophthalmology

2010: became svp BioOncology

2013: left Genentech to become global product strategy head/chief marketing officer at Genentech's parent company, Roche (ROG.S)

2016: returned to Genentech as head of North American operations

2017: appointed chief executive officer at Genentech

2019-2023: CEO of Roche Pharmaceutical

Sources: Roche and Bayer

Compiled by Josephine Mason. Editing by Jane Merriman

Our Standards: The Thomson Reuters Trust Principles.

Read Next